Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Rapid or accelerated tumor cell repopulation after significant tumor cell killing induced by various cytotoxic agents often compromises the expected therapeutic benefit of such tumor responses. Here, we discuss the concept that tumor cell repopulation after certain cytotoxic therapies, using vascular disrupting agents as an example, may be aided by a reactive, systemic host response involving the mobilization of bone marrow–derived circulating cells, including endothelial progenitor cells, which subsequently home to the vasculature of treated tumors and promote tumor neovascularization. These vasculogenic “rebounds” can be blocked, at least in some cases, by treatment with an antiangiogenic drug. There is limited preliminary evidence that maximum tolerated dose chemotherapy causes a similar effect. This could constitute one way by which antiangiogenic therapy could increase the efficacy of conventional cytotoxic chemotherapy regimens; it also raises the specter of new molecular targets for systemic cancer therapies which are involved in therapy-induced bone marrow–derived cell mobilization, homing to tumors, and tumor retention. [Cancer Res 2007;67(15):7055–8]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“In the case of specific antibody-targeting drugs, such as bevacizumab, the humanized monoclonal antivascular endothelial growth factor (VEGF) antibody, clinical benefit in some randomized phase III trials is observed when it is combined with chemotherapy, e.g., 5-fluorouracil/leucovorin and irinotecan for metastatic c…”
BackgroundLyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Cited by
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
Mancuso, P., Antoniotti, P., Quarna, J., Calleri, A., Rabascio, C., Tacchetti, C., Braidotti, P., Wu, H.-K., Zurita, A. J., Saronni, L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0432 · Cited by 164
Tumour endothelial cells acquire drug resistance in a tumour microenvironment
Hida, K., Akiyama, K., Ohga, N., Maishi, N., & Hida, Y. (2013) · Journal of Biochemistry · doi:10.1093/jb/mvs152 · Cited by 68
Host effects contributing to cancer therapy resistance.
Katz, O. B., & Shaked, Y. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.002 · Cited by 47
Self-citation
Metadata
- Authors
- Shaked, Y., & Kerbel, R. S.
- Venue
- Cancer Research
- Published
- 2007-08-01
- Volume
- 67
- Issue
- 15
- Pages
- 7055-7058
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2066697593
- Cited by
- 112
- References
- 3
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-0905
- The paper
- Shaked, Y., & Kerbel, R. S. (2007). Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-0905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.